



Clinical Data

CREST Study

The Largest Prospective Cohort in Interventional Glaucoma Procedures

Design



- Over 400 eyes
- 10+ sites
- 2+ years

3 Peer Reviewed Publications

- 12-month safety & efficacy (117 eyes)
- Post-Op safety analysis (243 eyes)
- 24-month safety & efficacy (31 eyes)

CREST Study

The Largest Prospective Cohort in Interventional Glaucoma Procedures




References:

*Ianchulev T, Weinreb RN, Calvo EA, Lewis J, Kamthan G, Sheybani A, Rhee DJ, Ahmed IK. Bio-Interventional Cyclodialysis and Allograft Scleral Reinforcement for Uveoscleral Outflow Enhancement in Open-Angle Glaucoma Patients: One-Year Clinical Outcomes. Clin Ophthalmol. 2024;18:3605-3614.

**Calvo E, De Francesco T, Vera L, Tyson F, Weinreb RN. Bio-Interventional Uveoscleral Outflow Enhancement Surgery for Primary Open Angle Glaucoma: 2-year results of cyclodialysis with scleral allograft reinforcement. Ophthalmology Science (2025).

Clinical Results Redefine Interventional Glaucoma

- ✓ Robust Efficacy
- ✓ MIGS-like Safety Profile
- ✓ Novel Technology: Bio-Interventional Glaucoma Surgery (BIGS)




Scientific presentations
and publications at



Ianchulev, T., Weinreb, R. N., Calvo, E. A., Lewis, J., Kamthan, G., Sheybani, A., Rhee, D. J., & Ahmed, I. K. (2024). Bio-Interventional Cyclodialysis and Allograft Scleral Reinforcement for Uveoscleral Outflow Enhancement in Open-Angle Glaucoma Patients: One-Year Clinical Outcomes. *Clinical ophthalmology (Auckland, N.Z.)*, 18, 3605–3614. <https://doi.org/10.2147/OPTH.S496631>

Holmes DP, Clement CI, Nguyen V, et al. Comparative study of 2-year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery. *Clin Exp Ophthalmol*. 2022;50(3):303-311. doi:10.1111/ceo.14048

UNLOCK Clinically Demonstrated IOP Reduction



Notes: Preliminary results at 24 months show little change in efficacy from 12 months.

24-Month Follow Up

> 70%

Of treated eyes achieved a $\geq 20\%$ reduction in IOP with the same or fewer glaucoma medications

> 55%

Decrease of IOP-lowering medications

**No Serious Ocular
Adverse Events**